Discovery and On-demand Provisioning of Real-World Web Services

Author(s):  
Dominique Guinard ◽  
Vlad Trifa ◽  
Patrik Spiess ◽  
Bettina Dober ◽  
Stamatis Karnouskos
Keyword(s):  
2014 ◽  
Vol 17 (6) ◽  
pp. 1301-1311 ◽  
Author(s):  
Hala S. Own ◽  
Hamdi Yahyaoui
Keyword(s):  

2011 ◽  
Vol 7 (2) ◽  
pp. 71
Author(s):  
Ivan Magdalenić ◽  
Danijel Radošević ◽  
Dragutin Kermek

The on demand generation of source code and its execution is essential if computers are expected to play an active role in information discovery and retrieval. This paper presents a model of implementation of a source code generator, whose purpose is to generate source code on demand. Theimplementation of the source code generator is fully configurable and its adoption to a new application is done by changing the generator configuration and not the generator itself. The advantage of using the source code generator is rapid and automatic development of a family of application once necessary program templates and generator configuration are made. The model of implementation of the source code generator is general and implemented source code generator can be used in differentareas. We use a source code generator for dynamic generation of ontology supported Web services for data retrieval and for building of different kind of web application.


Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 1132-1132
Author(s):  
Robert F. Sidonio ◽  
Angela C. Weyand ◽  
Dunlei Cheng ◽  
Crystal Watson

Background: Von Willebrand disease (VWD) is the most common inherited bleeding disorder in humans affecting up to 1% of the population, while symptomatic prevalence is likely closer to 0.1%. A deficiency of von Willebrand factor (VWF) can be quantitative (type 1 or type 3) or qualitative (type 2) and lead to a bleeding diathesis of variable intensity roughly correlating with functional activity. Diagnosis can be challenging due to variable penetrance and large influence of multiple pre-analytic variables and a wide testing coefficient of variation. Treatment for VWD is focused on replacement of defective or deficient VWF with a plasma-derived or recombinant VWF-containing product, release and elevation of endogenous stores of VWF with Desmopressin (DDAVP), or prevention of premature fibrinolysis with an antifibrinolytic, such as aminocaproic acid. Although there is relative consensus on the management of mild VWD, there is scarce literature about the optimal treatment of patients with severe disease, especially in regard to factor replacement. Real World evidence for the use of primary (prior to significant bleeding) or secondary (following development of significant bleeding) prophylaxis is lacking with the majority of studies relying heavily on retrospective data. Additionally, ongoing VWD prophylaxis studies typically only allow participants to enroll if they previously have not been on prophylaxis, limiting our ability to learn about this growing population of patients. Study Design and Methods: Approximately 1,900 VWD patients were identified in the ATHNdataset with a VWF:Ag or VWF:RCo of ≤ 30%, with ~170 of these on prophylaxis. This group, in addition to those VWD patients with clinically significant bleeding and ≤ 40% of normal VWF:Ag or VWF:RCo, provide a potential unmet opportunity to examine prophylaxis and treatment patterns. Furthermore, a standardized laboratory assessment (including a standardized diagnostic battery, genetic evaluation of VWF gene, and inhibitor testing) will provide significant enrichment of the ATHNdataset by fully characterizing patients that are highly likely to utilize factor concentrates. Inclusion criteria are patients with severe VWD defined as type 3 VWD, or VWF:RCo, VWF:GP1bM or VWF:Ag≤ 30%, patients with clinically severe VWD as defined by VWF:Rco, VWF:GP1bM or VWF:Ag ≤ 40% with severe bleeding phenotype requiring recurrent use of factor concentrates, and co-enrollment in the ATHNdataset. Patients with platelet-type or acquired VWD are excluded. The primary objective is to assess the safety of various VWF regimens for different indications (on-demand, surgery, and prophylaxis) in adult and pediatric patients with clinically severe VWD. Safety is measured by the number of reported events as defined by the European Haemophilia Safety Surveillance (EUHASS) program. Secondary objectives are to enrich and analyze data from clinically severe congenital VWD patients by collecting laboratory data; to establish sub-studies for patients who are treated with VWF products on demand or who have started on or switched to a particular VWF containing product; to evaluate the use of factor replacement as prophylaxis in a cohort of severe VWD participants over 6 month time periods; to describe bleeding events, changes in overall bleeding, and annualized bleed rate as measured by the International Society on Thrombosis and Haemostasis (ISTH) Bleeding Assessment Tool (BAT) and if applicable the Pictorial Bleed Assessment Chart (PBAC); and to describe real-world effectiveness of VWD treatment as measured by health care utilization and quality of life measures (PROMIS® and V-WIQ questionnaires). Descriptive statistics will be calculated to analyze the primary and secondary outcomes. For each categorical variable, its frequency and percentage will be reported. In terms of a continuous measurement, its mean, median, standard deviation, interquartile range, minimum, and maximum values will be disclosed. The study will attempt to enroll a target number of at least 50 participants who are receiving VONVENDI but will not mandate the use of VONVENDI. More study design details are outlined in Table 1. Disclosures Sidonio: Genetech: Membership on an entity's Board of Directors or advisory committees, Research Funding; Takeda-Shire: Membership on an entity's Board of Directors or advisory committees, Research Funding; Bioverativ: Membership on an entity's Board of Directors or advisory committees, Research Funding; Octapharma: Membership on an entity's Board of Directors or advisory committees, Research Funding; Grifols: Membership on an entity's Board of Directors or advisory committees, Research Funding; Biomarin: Membership on an entity's Board of Directors or advisory committees; Uniqure: Membership on an entity's Board of Directors or advisory committees; Novo Nordisk: Membership on an entity's Board of Directors or advisory committees; Kedrion: Research Funding.


2005 ◽  
Vol 15 (3) ◽  
pp. 403-430 ◽  
Author(s):  
VICTOR M. GULIAS ◽  
MIGUEL BARREIRO ◽  
JOSE L. FREIRE

In this paper, we present some experience of using the concurrent functional language Erlang to implement a distributed video-on-demand server. For performance reasons, the server is deployed in a cheap cluster made from off-the-shelf components. The demanding system requirements, in addition to the complex and ever-changing domain, suggested a highly flexible and scalable architecture as well as a quite sophisticated control software. Functional programming played a key role in the development, allowing us to identify functional abstractions throughout the system. Using these building blocks, large configurations can be defined using functional and process composition, reducing the effort spent on adapting the system to the frequent changes in requirements. The server evolved from a prototype that was the result of a project supported by a regional cable company, and it is currently being used to provide services for real-world users. Despite our initial concerns, efficiency has not been a major issue.


Bioanalysis ◽  
2021 ◽  
Author(s):  
Scott Davis ◽  
Joel Usansky ◽  
Shibani Mitra-Kaushik ◽  
John Kellie ◽  
Kimberly Honrine ◽  
...  

Challenges for data storage during drug development have become increasingly complex as the pharmaceutical industry expands in an environment that requires on-demand availability of data and resources for users across the globe. While the efficiency and relative low cost of cloud services have become increasingly attractive, hesitancy toward the use of cloud services has decreased and there has been a significant shift toward real-world implementation. Within GxP laboratories, the considerations for cloud storage of data include data integrity and security, as well as access control and usage for users around the globe. In this review, challenges and considerations when using cloud storage options for the storage of laboratory-based GxP data are discussed and best practices are defined.


Author(s):  
Gergely Sipos ◽  
Péter Kacsuk

This chapter summarizes the most relevant results that grid research achieved in the last decade, it presents the actual issues of the topic, and it outlines how current and future results from this area can contribute to smart organizations. At the first place the basic goal of the Grid is presented and its state-of-the-art, service-based realization is discussed. This global infrastructure will one day connect together diverse types of hardware and software elements, abstracting them out as intelligent autonomous agents that can discover and collaborate with each other on demand. The middle part of the chapter introduces two potential middleware technologies that service grids can be built on. They are the Web services-based open grid services architecture (OGSA) and Jini. The final part of the chapter presents the future of service grids and the important role these flexible infrastructures will probably have in the life of smart organizations.


2008 ◽  
pp. 206-227
Author(s):  
Konstantin Beznosov

This chapter reports on our experience of designing and implementing an architecture for protecting enterprise-grade Web service applications hosted by ASP.NET. Security mechanisms of Microsoft ASP.NET container—a popular hosting environment for Web services—have limited scalability, flexibility, and extensibility. They are therefore inade-quate for hosting enterprise-scale applications that need to be protected according to diverse and/or complex application-specific security policies. To overcome the limitations of ASP.NET security, we developed a flexible and extensible protection architecture. Deployed in a real-world security solution at a financial organization, the architecture enables integra-tion of ASP.NET into the organizational security infrastructure with reduced effort on the part of Web Service developers. Throughout this report, we discuss our design decisions, suggest best practices for constructing flexible and extensible authentication and authoriza-tion logic for Web Services, and share lessons learned.


Author(s):  
Edward Mac Gillavry

The collection and dissemination of geographic information has long been the prerogative of national mapping agencies. Nowadays, location-aware mobile devices could potentially turn everyone into a mapmaker. Collaborative mapping is an initiative to collectively produce models of real-world locations online that people can then access and use to virtually annotate locations in space. This chapter describes the technical and social developments that underpin this revolution in mapmaking. It presents a framework for an alternative geographic information infrastructure that draws from collaborative mapping initiatives and builds on established Web technologies. Storing geographic information in machine-readable formats and exchanging geographic information through Web services, collaborative mapping may enable the “napsterisation” of geographic information, thus providing complementary and alternative geographic information from the products created by national mapping agencies.


Sign in / Sign up

Export Citation Format

Share Document